We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-14.56%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$688M
AUM Growth
-$52M
Cap. Flow
-$179M
Cap. Flow %
-26.07%
Top 10 Hldgs %
65.57%
Holding
231
New
46
Increased
68
Reduced
48
Closed
42

Sector Composition

Rank Sector Weight
1 Miscellaneous 74.53%
2 Healthcare 8.91%
3 Financials 5.9%
4 Technology 5.82%
5 Consumer Discretionary 1.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PDSB icon
126
PUT
PDS Biotechnology
PDSB
$22.3M
$305K 0.04%
376
+92
+32% +$990
KUST
127
PUT
Kustom Entertainment Inc
KUST
$4.22M
0
BEATW icon
128
Heartbeam Inc Warrant
BEATW
$21.2K
$270K 0.04%
+360,391
New +$359K
RKDA icon
129
Arcadia Biosciences
RKDA
$1.04M
$263K 0.04%
+6,330
New +$413K
CBAT icon
130
CBAK Energy Technology Ltd
CBAT
$88.6M
$262K 0.04%
167,774
+150,226
+856% +$310K
DXR icon
131
Daxor
DXR
$67M
$237K 0.03%
20,996
-36,928
-64% -$407K
LSTA icon
132
PUT
Lisata Therapeutics
LSTA
$14.7M
$225K 0.03%
178
-246
-58% -$3.8K
CTRM icon
133
PUT
Castor Maritime
CTRM
$24.1M
$193K 0.03%
136
-125
-48% -$2.57K
NMTR
134
CALL
DELISTED
9 Meters Biopharma
NMTR
$192K 0.03%
98
-85
-46% -$1.9K
CRDL
135
Cardiol Therapeutics
CRDL
$232M
$184K 0.03%
+99,440
New +$275K
ADTX
136
PUT
DELISTED
ADITXT INC
ADTX
0
XELA
137
DELISTED
Exela Technologies, Inc. Common Stock
XELA
$182K 0.03%
+52
New +$305K
HMCOW
138
DELISTED
HumanCo Acquisition Corp. Warrant
HMCOW
$176K 0.03%
200,314
ZVRA icon
139
Zevra Therapeutics
ZVRA
$716M
$174K 0.03%
20,000
-21,531
-52% -$192K
HCDIP
140
DELISTED
Harbor Custom Development, Inc. 8.0% Series A Cumulative Convertible Preferred Stock, no par value
HCDIP
0
ORIO
141
PUT
Orion Digital Corp
ORIO
$24.8M
$167K 0.02%
163
-1,672
-91% -$24.1K
PMCB icon
142
PUT
PharmaCyte Biotech
PMCB
$4.21M
$166K 0.02%
665
+224
+51% +$617
SBEV.WS
143
DELISTED
Splash Beverage Group, Inc. Warrants to purchase 1/40th of a share of Common Stock at an exercise price of $184.00
SBEV.WS
$156K 0.02%
503,266
-102,393
-17% -$40K
GFAI icon
144
Guardforce AI
GFAI
$10.7M
$136K 0.02%
3,147
-15,044
-83% -$1.25M
CTXR icon
145
PUT
Citius Pharmaceuticals
CTXR
$15.9M
$129K 0.02%
34
+14
+70% +$635
GLBS icon
146
PUT
Globus Maritime Ltd
GLBS
$80.3M
$128K 0.02%
608
-651
-52% -$1.74K
SRGA
147
PUT
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$127K 0.02%
59
NMRD
148
PUT
DELISTED
Nemaura Medical, Inc. Common Stock
NMRD
$125K 0.02%
275
-1,043
-79% -$5.62K
BBLGW
149
Bone Biologics Corp Warrants
BBLGW
$18.3M
$116K 0.02%
+5,516
New +$138K
PMCB icon
150
CALL
PharmaCyte Biotech
PMCB
$4.21M
$108K 0.02%
+431
New +$1.19K

Similar funds

Sabby Management's Q4 2021 Portfolio in Review

As of Q4 2021, Sabby Management held 231 positions worth $688M, down 7% from $740M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sabby Management withdrew a net $179M in Q4 2021, closing 42 positions and reducing 48 holdings. Its most notable exit was Tricida, Inc. Common Stock, an estimated $3.06M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 75% of assets, down from 77% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Sabby Management opened a new position in AIOS Tech worth $10.4M.

  • Sabby Management's largest Q4 2021 buy was AIOS Tech: 16,134 shares worth $10.4M.
  • Sabby Management added most to Acutus Medical Inc in Q4 2021, an estimated $3.52M increase.
  • Sabby Management's biggest Q4 2021 reduction was iPath Series B S&P 500 VIX Short-Term Futures ETN, cutting an estimated $3.33M.
  • Sabby Management fully exited Tricida, Inc. Common Stock in Q4 2021, selling an estimated $3.06M.
  • Sabby Management's ten largest holdings make up 66% of its $688M portfolio in Q4 2021.
  • Sabby Management opened 46 new positions and closed 42 in Q4 2021.
  • Sabby Management's portfolio value fell 7% quarter-over-quarter to $688M.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.